{"url_path":"/sec/aidx/8-k/2026-07-22/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-080432-index.html","accession_number":"0001213900-26-080432","cik":"0001139685","ticker":"AIDX","issuer_name":"20/20 Biolabs, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-080432-index.html","primary_entity_key":"0001139685","primary_entity_name":"20/20 Biolabs, Inc."},"word_count":301,"has_tables":true,"body_markdown":"** **\n\n**Item\n3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**\n\n \n\nOn July 17, 2026, the Company received a written\nnotification from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the\n$1.00 closing bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) for the 30\nconsecutive business days from June 3, 2026 to July 16, 2026.\n\n \n\nPursuant to Nasdaq Listing Rule 5810(c)(3)(A),\nthe Company has been granted a 180-calendar day compliance period, or until January 13, 2027, to regain compliance with the Bid Price\nRule. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for at least ten\n(10) consecutive business days during the 180-calendar day compliance period.\n\n \n\nIn the event that the Company is not in compliance\nby January 13, 2027, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the\nCompany will be required to meet the continued listing requirement for the market value of publicly held shares and all other initial\nlisting standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and will need to provide written notice of\nits intention to cure the deficiency during the second compliance period. If the Company does not regain compliance within the allotted\ncompliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s common\nstock will be subject to delisting.\n\n \n\nThe Company intends to monitor the closing bid\nprice of its common stock and may, if appropriate, consider implementing available options to cure the deficiency and regain compliance\nwith the Bid Price Rule within the compliance period(s) under Nasdaq’s Listing Rules."}